Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Melanoma & Skin Cancer Articles

Adjuvant Ipilimumab Improves OS in High-Risk Melanoma
Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.
CTC Detection Linked to Relapse in Stage III Melanoma
The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.
ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year
Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.
Investigators Tackle Resistance, Poor Response in Metastatic Melanoma
Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.
Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma. 
Treatment-Related Dermatologic AEs in Melanoma Require Careful Management
Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.
Targeting the Hedgehog Pathway Holds Promises and Pitfalls
Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.
Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.
Guiding Treatment Decisions in Newly Diagnosed Metastatic Melanoma
Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.
Biomarker Hunt Finds Potential With ctDNA in Melanoma
David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma. 
Publication Bottom Border
Border Publication